Verona Pharma plc (VRNA)
NASDAQ: VRNA · Real-Time Price · USD
62.27
-0.43 (-0.69%)
Mar 31, 2025, 1:13 PM EDT - Market open
Verona Pharma Revenue
In the year 2024, Verona Pharma had annual revenue of $42.28M. Verona Pharma had revenue of $36.66M in the quarter ending December 31, 2024.
Revenue (ttm)
$42.28M
Revenue Growth
n/a
P/S Ratio
120.92
Revenue / Employee
$202,292
Employees
209
Market Cap
5.29B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
VRNA News
- 3 days ago - Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS - GlobeNewsWire
- 4 weeks ago - Verona Pharma plc (VRNA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - Verona Pharma Announces March 2025 Investor Conference Participation - GlobeNewsWire
- 6 weeks ago - Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update - GlobeNewsWire
- 2 months ago - Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited - Seeking Alpha
- 2 months ago - Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights - GlobeNewsWire
- 4 months ago - Verona Pharma Announces December 2024 Investor Conference Participation - GlobeNewsWire